Full-Time

Finance Manager-R&D Finance FP&a

Development Functions Finance

Posted on 4/24/2025

Deadline 5/1/25
Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals

Compensation Overview

$136.3k - $176.4k/yr

+ Bonus + Stock-based long-term incentives

Senior

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
SAP Products
Financial analysis
Excel/Numbers/Sheets
Requirements
  • BS/BA with 6+ years / or MS/MA with 4+ years of relevant experience in FP&A
  • Strong verbal, visual and written communication skills
  • Strong technical skills and interest in Financial Systems and Tools (including SAP)
  • Advanced proficiency in Microsoft Excel and PowerPoint
  • Demonstrated problem solving and analytical abilities
Responsibilities
  • Provide ongoing analytical support including preparing budgets and forecasts
  • Prepare monthly reporting and variance analysis
  • Provide input for continuous improvement in support of forecast cycles and monthly close processes
  • Perform ad-hoc business analysis and preparation of documentation in support of R&D leadership and internal finance analysis
  • Responsible for month-end close activities involving functional accruals, reclasses, prepaids and other journal entries
  • Responsible for monitoring key performance indicators, highlighting trends and analyzing causes of unplanned variances
  • Collaborate with other FP&A functions to ensure alignment of information, completeness, and timeliness of submissions
  • Provide financial analysis to support tactical and strategic decision making for OPEX and HC
  • Streamline and centralize data collection process through SAP functionalities and tools
Desired Qualifications
  • Experience in biotech, or pharmaceuticals industry a plus, but not required

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and ensure sustainable practices. The company's goal is to enhance health equity and access to care, working with communities globally to remove barriers to healthcare and make its medicines available to those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's $32 billion U.S. investment will create over 3,000 jobs by 2028.
  • The reformulation of lenacapavir offers long-acting HIV prevention, improving patient adherence.
  • Gilead's top five ranking in the Most JUST list highlights its corporate responsibility.

What critics are saying

  • A $202 million settlement for legal violations may damage Gilead's reputation.
  • Layoffs of 150 employees, including senior management, could disrupt company operations.
  • AI-driven drug discovery companies pose a competitive threat to Gilead's traditional R&D.

What makes Gilead Sciences unique

  • Gilead focuses on innovative medicines for unmet needs like HIV/AIDS and liver diseases.
  • The company invests heavily in R&D to maintain a robust pipeline of new treatments.
  • Gilead's partnerships enhance product offerings and expand market reach globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Fierce Pharma
May 8th, 2025
Gilead tees up $11B in new US manufacturing, R&D investments

This time it's Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.

Gilead Sciences
May 7th, 2025
Gilead U.S. Investment to Create $43 Billion in Value to U.S. Economy

Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028

Constantine Cannon
May 5th, 2025
Gilead Pays $202M to Settle False Claims Act Kickback Charges

On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.

Financial Modeling Prep
May 2nd, 2025
Amgen Inc. (NASDAQ:AMGN) Surpasses Earnings and Sales Estimates in Q1 2025

Amgen competes with other biotech giants like Gilead Sciences and Biogen.

SFist
Apr 2nd, 2025
April Fool's Day Around the Bay: Bob Lee's Family Has Sued His Convicted Killer Nima Momeni

Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.

INACTIVE